Prevalence, Diagnostic Utility and Associated Characteristics of Bronchodilator Responsiveness.

BDR prevalence in patients with chronic airway diseases on treatment ranges from 18-30%, being modestly lower with the 2021 compared with 2005 ERS/ATS criteria, and is associated with lower lung function and greater symptom burden. These observations question the validity of BDR as a key diagnostic tool for asthma managed in clinical practice or as a standard inclusion criterion for clinical trials of asthma, and instead suggest BDR be considered a treatable trait for chronic airways disease.